Corifollitropin Alfa for Controlled Ovarian Stimulation in Assisted Reproductive Technologies: State of the Art.

Rev Bras Ginecol Obstet · 2023 · PMC10021006 · PMID 36878252

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

However, if rFSH is administered from day 8 onwards, a nonsignificant trend toward premature progesterone elevation was detected, with no significant difference between corifollitropin and daily rFSH. 16 Finally, multiple pregnancies tended to be more frequent for corifollitropin alfa (+ 4.4% absolute risk increase) than for daily rFSH in the ENGAGE Trial. 3 Flexible

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.